Literature DB >> 12586359

Ghrelin and growth hormone secretagogue receptor are expressed in the rat adrenal cortex: Evidence that ghrelin stimulates the growth, but not the secretory activity of adrenal cells.

Paola G Andreis1, Ludwik K Malendowicz, Marcin Trejter, Giuliano Neri, Raffaella Spinazzi, Gian Paolo Rossi, Gastone G Nussdorfer.   

Abstract

Ghrelin is an endogenous ligand of the growth hormone secretagogue receptor (GHS-R), which has been originally isolated from rat stomach. Evidence has been previously provided that adrenal gland possesses abundant ghrelin-displaceable GHS-Rs, but nothing is known about the possible role of ghrelin in the regulation of adrenocortical function. Reverse transcription-polymerase chain reaction demonstrated the expression of ghrelin and GHS-R in the rat adrenal cortex, and high adrenal concentrations of immunoreactive ghrelin were detected by radioimmune assay (RIA). Autoradiography localized abundant [(125)I]ghrelin binding sites in the adrenal zona glomerulosa (ZG) and outer zona fasciculata (ZF). Ghrelin (from 10(-10) to 10(-8) M) did not affect either basal steroid hormone (pregnenolone, progesterone, 11-deoxycorticosterone, corticosterone, 18-hydroxycorticosterone and aldosterone) secretion from dispersed ZG and zona fasciculata/reticularis (ZF/R) cells (as evaluated by quantitative high pressure liquid chromatography), or basal and agonist-stimulated aldosterone and corticosterone production from cultured ZG and ZF/R cells, respectively (as measured by RIA). Ghrelin (10(-8) and 10(-6) M) raised basal, but not agonist-stimulated, proliferation rate of cultured ZG cells (percent of cells able to incorporate 5-bromo-2'-deoxyuridine), without affecting apoptotic deletion rate (percent of cells able to incorporate biotinylated nucleosides into apoptotic DNA fragments). The tyrosine kinase (TK) inhibitor tyrphostin-23 and the p42/p44 mitogen-activated protein kinase (MAPK) inhibitor PD-98059 abolished the proliferogenic effect of 10(-8) M ghrelin, while the protein kinase A and C inhibitors H-89 and calphostin-C were ineffective. Ghrelin (10(-8) M) stimulated TK and MAPK activity of dispersed ZG cells, and the effect was abolished by preincubation with tyrphostin-23 and PD-98059, respectively. Tyrphostin-23 annulled ghrelin-induced activation of MAPK activity. Taken together, the present findings indicate that (i) ghrelin and GHS-R are both expressed in the rat adrenal cortex, ghrelin binding sites being very abundant in the ZG; (ii) ghrelin does not affect the secretory activity of rat adrenocortical cells, but significantly enhances the proliferation rate of cultured ZG cells, without affecting apoptotic deletion rate; and (iii) the ZG proliferogenic action of ghrelin involves the TK-dependent activation of the p42/p44 MAPK cascade.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586359     DOI: 10.1016/s0014-5793(03)00051-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  20 in total

Review 1.  Clinical application of ghrelin in the field of surgery.

Authors:  Shuji Takiguchi; Kohei Murakami; Yoshitomo Yanagimoto; Akihiro Takata; Yasuhiro Miyazaki; Masaki Mori; Yuichiro Doki
Journal:  Surg Today       Date:  2014-11-01       Impact factor: 2.549

2.  Regulation of ERK1/2 activity by ghrelin-activated growth hormone secretagogue receptor 1A involves a PLC/PKCvarepsilon pathway.

Authors:  Delphine Mousseaux; Lionel Le Gallic; Joanne Ryan; Catherine Oiry; Didier Gagne; Jean-Alain Fehrentz; Jean-Claude Galleyrand; Jean Martinez
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

3.  Hypothalamic ghrelin treatment modulates NPY-but not CRH-ergic activity in adrenalectomized rats subjected to food restriction: Evidence of a novel hypothalamic ghrelin effect.

Authors:  Eduardo Spinedi; Marie-Jeanne Voirol; Chantal Verdumo; Marco Giacominni; François Pralong; Rolf C Gaillard
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

4.  Ghrelin antagonized 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells.

Authors:  Juanjuan Dong; Ning Song; Junxia Xie; Hong Jiang
Journal:  J Mol Neurosci       Date:  2008-12-04       Impact factor: 3.444

5.  Irregular and frequent cortisol secretory episodes with preserved diurnal rhythmicity in primary adrenal Cushing's syndrome.

Authors:  M O van Aken; A M Pereira; S W van Thiel; G van den Berg; M Frölich; J D Veldhuis; J A Romijn; F Roelfsema
Journal:  J Clin Endocrinol Metab       Date:  2004-12-14       Impact factor: 5.958

6.  Ghrelin localization in rat and human thyroid and parathyroid glands and tumours.

Authors:  Kawtar Raghay; Tomás García-Caballero; Rubén Nogueiras; Gérard Morel; Andrés Beiras; Carlos Diéguez; Rosalía Gallego
Journal:  Histochem Cell Biol       Date:  2005-09-27       Impact factor: 4.304

7.  Ghrelin immunoexpression in pituitary adenomas.

Authors:  Fabio Rotondo; Michael Cusimano; Bernd W Scheithauer; Angelo Rotondo; Luis V Syro; Kalman Kovacs
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

Review 8.  Ghrelin, hypothalamus-pituitary-adrenal (HPA) axis and Cushing's syndrome.

Authors:  Roberta Giordano; Andreea Picu; Fabio Broglio; Lorenza Bonelli; Matteo Baldi; Rita Berardelli; Ezio Ghigo; Emanuela Arvat
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

9.  Ghrelin, peptide YY and their receptors: gene expression in brain from subjects with and without Prader-Willi syndrome.

Authors:  Zohreh Talebizadeh; Nataliya Kibiryeva; Douglas C Bittel; Merlin G Butler
Journal:  Int J Mol Med       Date:  2005-04       Impact factor: 4.101

10.  Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways.

Authors:  Talat Waseem; Mark Duxbury; Hiromichi Ito; Stanley W Ashley; Malcolm K Robinson
Journal:  Surgery       Date:  2007-12-27       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.